Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC)

By sjmartinez • April 7, 2023

Wu TC, Stube A, Felix C, Oseguera D, Romero T, Goldman J, Garon EB, Lee JM, Glaspy J, Lisberg AE, Rusthoven CG, Camidge DR, Siva S, Solomon B, Lee A, Tenn SE, Shaverdian N, Steinberg ML, Raldow AC, Lee P. Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC). Int J Radiat Oncol Biol Phys. 2023 Apr 4:S0360-3016(23)00325-5. doi: 10.1016/j.ijrobp.2023.03.069. Epub ahead of print. PMID: 37023987.

Tags: Hematology/Oncology, Publications

Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of Disease

Fine SA, Lim SY, Siena NM, de Jesus AB, Goh T, Markus L, Russell TA, Kendal JK, Lofftus SY, Shehata MS, Dao HB, Lee A,[...]

Elevated Adrenocorticotropic Hormone After Adrenalectomy or Adrenal Ablation and Immune Checkpoint Inhibitors: Adrenal Insufficiency Is Not Always the Culprit

Shabsovich D, Kathuria-Prakash N, Zhang J, Cabral M, Lopez L, Sumal A, Drakaki A. Elevated Adrenocorticotropic Hormone After Adrenalectomy or Adrenal Ablation and Immune Checkpoint[...]

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)

Wong MK, Milhem MM, Sacco JJ, Michels J, In GK, Couselo EM, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Wise-Draper TM, Bowles TL, Tsai[...]